CA2233748A1 - Medicament - Google Patents
Medicament Download PDFInfo
- Publication number
- CA2233748A1 CA2233748A1 CA 2233748 CA2233748A CA2233748A1 CA 2233748 A1 CA2233748 A1 CA 2233748A1 CA 2233748 CA2233748 CA 2233748 CA 2233748 A CA2233748 A CA 2233748A CA 2233748 A1 CA2233748 A1 CA 2233748A1
- Authority
- CA
- Canada
- Prior art keywords
- lisinopril
- administered
- pharmaceutical composition
- retinopathy
- diabetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2233748 CA2233748A1 (fr) | 1998-03-31 | 1998-03-31 | Medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2233748 CA2233748A1 (fr) | 1998-03-31 | 1998-03-31 | Medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2233748A1 true CA2233748A1 (fr) | 1999-09-30 |
Family
ID=29275463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2233748 Abandoned CA2233748A1 (fr) | 1998-03-31 | 1998-03-31 | Medicament |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2233748A1 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001064205A3 (fr) * | 2000-03-02 | 2002-04-25 | Janet Sredy | Compositions contenant un acide indol-alkanoique substitue et inhibiteur d'enzyme de conversion de l'angiotensine |
| EP1656941A1 (fr) * | 2004-11-09 | 2006-05-17 | Clinigene International Private Limited | Préparations pharmaceutiques pour le traitement de la nephropathie diabétique |
| US7728033B2 (en) | 2003-05-05 | 2010-06-01 | Clinigene International Private Limited | Mycophenolate mofetil in diabetic nephropathy |
-
1998
- 1998-03-31 CA CA 2233748 patent/CA2233748A1/fr not_active Abandoned
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001064205A3 (fr) * | 2000-03-02 | 2002-04-25 | Janet Sredy | Compositions contenant un acide indol-alkanoique substitue et inhibiteur d'enzyme de conversion de l'angiotensine |
| US6521659B2 (en) | 2000-03-02 | 2003-02-18 | Institute For Pharmaceutical Discovery, Llc | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
| US7728033B2 (en) | 2003-05-05 | 2010-06-01 | Clinigene International Private Limited | Mycophenolate mofetil in diabetic nephropathy |
| EP1656941A1 (fr) * | 2004-11-09 | 2006-05-17 | Clinigene International Private Limited | Préparations pharmaceutiques pour le traitement de la nephropathie diabétique |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6369103B1 (en) | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor | |
| RU2298418C2 (ru) | Комбинация по меньшей мере двух соединений, выбранных из групп антагонистов at1-рецептора или ингибиторов асе (ангиотензинпревращающий фермент), или ингибиторов hmg-coa-редуктазы (бета-гидрокси-бета-метилглутарил-кофермент-а-редуктаза) | |
| Fogari et al. | Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function | |
| Bianchi et al. | Microalbuminuria in patients with essential hypertension: effects of an angiotensin converting enzyme inhibitor and of a calcium channel blocker | |
| SK287792B6 (sk) | Farmaceutické kombinácie a kompozície obsahujúce kyselinu (E)-7-{4-(4-fluórfenyl)-6-izopropyl-2- [metyl(metylsulfonyl)amino]pyrimidin-5-yl}-(3R, 5S)-3,5-dihydroxyhept-6-énovú | |
| RU2216354C2 (ru) | Фармацевтические композиции, включающие ингибитор альдегидредуктазы и ингибитор асе | |
| EP0220107A2 (fr) | Utilisation des inhibiteurs de l'enzyme convertissant l'angiotensine dans la dégénération maculaire | |
| EP4142770A1 (fr) | Semaglutide pour le traitement de la stéatohépatite non alcoolique | |
| JP2011137023A (ja) | コレステロール低下薬の使用 | |
| Jin et al. | Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy | |
| CA2233748A1 (fr) | Medicament | |
| Preston et al. | Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus | |
| Capewell et al. | A trial of the calcium antagonist felodipine in hypertensive type 2 diabetic patients | |
| Cifkova et al. | Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension | |
| JP2007513991A (ja) | メタボリック症候群の処置のためのスタチンの使用 | |
| Pool et al. | Clinical experience and rationale for angiotensin-converting enzyme inhibition with lisinopril as the initial treatment for hypertension in older patients | |
| Karpati et al. | Long-term tolerability and efficacy of the fixed combination of manidipine and delapril in patients with essential hypertension | |
| Smith | The treatment of hypertension in patients with diabetes | |
| Fevrier et al. | Swiss hypertension treatment programme with verapamil and/or enalapril in diabetic patients | |
| Padilla et al. | Treatment of hypertension in type 2 diabetes | |
| Bouchacourt et al. | Rationale for ACE inhibition in the elderly: treatment of arterial hypertension with enalapril | |
| Adalet et al. | Trandolapril in overweight patients with mild-to-moderate essential hypertension: the turkish multicenter trandolapril study | |
| Unger | Lessons from ALLHAT: Are low budget diuretics first line therapy in hypertension? | |
| Unger | Lessons from ALLHAT | |
| Chandramouli et al. | Use of ACE inhibitors in diabetic and nondiabetic patients with renal disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |